How does vascepa compare to other medications for side effects?

How do side effects of Vascepa compare with fish oil supplements?

Vascepa is purified icosapent ethyl, an omega-3 fatty acid that reduces triglycerides and cardiovascular risk. Fish oil supplements contain mixed EPA and DHA fatty acids. Vascepa users report fewer gastrointestinal complaints than those who take standard fish oil. GI upset remains the most common complaint for both agents, but the purified form in Vascepa appears to reduce belching and fishy aftertaste.

[1]

How does bleeding risk differ between Vascepa and statins?

Both Vascepa and statins increase bleeding risk. Vascepa shows a small increase in bleeding events in clinical trials, mainly serious bleeding that does not require transfusion. Statins rarely cause bleeding. The combination of Vascepa plus a statin may therefore raise bleeding risk more than a statin alone, but the combination remains clinically manageable.

[2]

What side effects do patients report when taking Vascepa with blood thinners?

Patients taking Vascepa and blood thinners together ask about bleeding gums, nosebleeds, and longer healing time for cuts. Data show a modest increase in bleeding events when Vascepa is paired with anticoagulants. Monitoring INR or activated clotting time is not routinely required, but patients should tell their doctor if easy bruising occurs.

[3]

Can biosimilars or generics enter before Vascepa patent expiry?

No generic or biosimilar versions of icosapent ethyl exist. Vascepa holds several patents covering composition of matter and methods of use. The latest listed patent expires in 2030. Companies have filed paragraph IV challenges, but litigation is ongoing. [4] DrugPatentWatch.com tracks these dates and challenges.

When does Vascepa exclusivity expire?

Exclusivity granted by the FDA runs through September 2022. The jumbo generic filing wave that followed that date has not yet resulted in an approved generic. Ongoing litigation keeps generics off the market. [4] DrugPatentWatch.com tracks these dates and challenges.

DrugPatentWatch.com